Plazomicin | CAS# 1154757-24-0 | Antibiotic

MedKoo Cat#: 571518 | Name: Plazomicin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Plazomicin is a next-generation aminoglycoside that has been designed as an antibiotic to avoid resistance through aminoglycoside-modifying enzymes. Plazomicin demonstrates high activity against the Enterobacteriaceae including extended spectrum beta lactamase and most carbapenemase producers, and can be useful in treating complicated urinary tract infections (cUTIs) and acute pyelonephritis. It is undergoing Phase III clinical studies.

Chemical Structure

Plazomicin

CAS#1154757-24-0 (free)

Theoretical Analysis

MedKoo Cat#: 571518

Name: Plazomicin

CAS#: 1154757-24-0 (free)

Chemical Formula: C25H48N6O10

Exact Mass: 592.3432

Molecular Weight: 592.69

Elemental Analysis: C, 50.66; H, 8.16; N, 14.18; O, 26.99

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

1154757-24-0 (free) 1380078-95-4 (sulfate)

Synonym

Plazomicin; ACHN-490; ACHN 490; ACHN490;

IUPAC/Chemical Name

(S)-4-amino-N-((1R,2S,3S,4R,5S)-5-amino-4-(((2R,3R)-3-amino-6-(((2-hydroxyethyl)amino)methyl)-3,4-dihydro-2H-pyran-2-yl)oxy)-2-(((2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)tetrahydro-2H-pyran-2-yl)oxy)-3-hydroxycyclohexyl)-2-hydroxybutanamide

InChi Key

IYDYFVUFSPQPPV-PEXOCOHZSA-N

InChi Code

InChI=1S/C25H48N6O10/c1-25(37)11-38-24(18(35)21(25)29-2)41-20-15(31-22(36)16(33)5-6-26)9-14(28)19(17(20)34)40-23-13(27)4-3-12(39-23)10-30-7-8-32/h3,13-21,23-24,29-30,32-35,37H,4-11,26-28H2,1-2H3,(H,31,36)/t13-,14+,15-,16+,17+,18-,19-,20+,21-,23-,24-,25+/m1/s1

SMILES Code

CN[C@@H]1[C@H]([C@H](OC[C@@]1(O)C)O[C@@H]2[C@H]([C@@H]([C@H](C[C@H]2NC([C@H](CCN)O)=O)N)O[C@H]3OC(CNCCO)=CC[C@H]3N)O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 592.69 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548540/ PubMed PMID: 31643858. 2: Abdul-Mutakabbir JC, Kebriaei R, Jorgensen SCJ, Rybak MJ. Teaching an Old Class New Tricks: A Novel Semi-Synthetic Aminoglycoside, Plazomicin. Infect Dis Ther. 2019 Jun;8(2):155-170. doi: 10.1007/s40121-019-0239-0. Epub 2019 Mar 9. Review. PubMed PMID: 30850956; PubMed Central PMCID: PMC6522576. 3: Eljaaly K, Alharbi A, Alshehri S, Ortwine JK, Pogue JM. Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections. Drugs. 2019 Feb;79(3):243-269. doi: 10.1007/s40265-019-1054-3. Review. PubMed PMID: 30723876. 4: Shaeer KM, Zmarlicka MT, Chahine EB, Piccicacco N, Cho JC. Plazomicin: A Next-Generation Aminoglycoside. Pharmacotherapy. 2019 Jan;39(1):77-93. doi: 10.1002/phar.2203. Epub 2019 Jan 8. Review. PubMed PMID: 30511766. 5: McCarthy MW. Plazomicin for the treatment of patients with complicated urinary tract infection. Drugs Today (Barc). 2018 Sep;54(9):513-518. doi: 10.1358/dot.2018.54.9.2874063. Review. PubMed PMID: 30303492. 6: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK513053/ PubMed PMID: 30000983. 7: Karaiskos I, Souli M, Giamarellou H. Plazomicin: an investigational therapy for the treatment of urinary tract infections. Expert Opin Investig Drugs. 2015;24(11):1501-11. doi: 10.1517/13543784.2015.1095180. Epub 2015 Sep 30. Review. PubMed PMID: 26419762. 8: Zhanel GG, Lawson CD, Zelenitsky S, Findlay B, Schweizer F, Adam H, Walkty A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther. 2012 Apr;10(4):459-73. doi: 10.1586/eri.12.25. Review. PubMed PMID: 22512755.